Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis treatment recommended

Sanofi-aventis treatment recommended

27th May 2008

A new chemotherapy drug from Sanofi-aventis has been recommended for the treatment of women with high-risk node-negative early stages of breast cancer following a recent trial.

It is reported that research on the Taxotere drug undertaken by Grupo Espanol de
Investigacion en Cancer de Mama (GEICAM), found that there was evidence to suggest the treatment could improve levels of Disease Free Survival.

Sanofi-aventis will see the full results of the research presented at this year’s American Society of Clinical Oncology meeting, which takes place in Chicago on Monday June 2nd.

Commenting on the news, GEICAM chair and principal investigator Professor Miguel Martin said that the results meant good news for many patients.

“This study showed that the TAC regimen improves Disease Free Survival in women with high risk node-negative breast cancer,” he said.

World Health Organization statistics claim breast cancer is globally the most common form of cancer found in women.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.